Primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) produces a cell-mediated immune response which is still present 1 year later  by Moreno, Javier et al.
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Canine  leishmaniasis,  an  important  zoonotic  disease  of  dogs,  is  the result  of an ineffective
and  inappropriate  immune  response  to infection  with  Leishmania  infantum.  It is  widely
accepted  that  the appropriate  immune  response  is  characterised  by  a T-helper  (Th)1-
dominated  proﬁle  in  an  overall  mixed  Th1/Th2  response.  The  absence  of  a strong  Th1
response  is  associated  with  progression  to the  clinical  disease.  Thus,  there  is  a need  for
an effective  vaccine  that  could  modulate  the  immune  response  to  a  more  appropriate
proﬁle  against  the  parasite.  In this  study  we  measured  the  impact  of  the LiESP/QA-21
canine  vaccine,  recently  launched  commercially  in  Europe,  on selected  humoral  and  cellu-
lar immune  markers  for  one  year after  a primary  vaccination  course.  The  humoral  response
to vaccination  was  characterised  by  a  predominantly  IgG2  proﬁle.  Vaccinated  dogs  devel-
oped long-lasting  cell-mediated  immune  responses  against  L.  infantum,  speciﬁcally  withitric oxide a stronger  ability  of macrophages  to  reduce  intracellular  parasite  burdens  in co-culture
with autologous  lymphocytes  compared  to control  dogs  (p  =  0.0002),  which  was  correlated
with  induction  of inducible  nitric  oxide  synthase  (iNOS)  and  production  of  nitric  oxide (NO)
derivatives.  These  results  conﬁrm  that vaccination  with  LiESP/QA-21  is  capable  of  inducing
an  appropriate  Th1-dominated  immune  proﬁle  which  persists  for a full  year.
©Abbreviations: BrdU, 5-bromo-2-deoxyuridine; CMLA, Canine
acrophage Leishmanicidal Assay; ELISpot, Enzyme-Linked Immunospot
ssay; IFAT, immunoﬂuorescent antibody test; iNOS, inducible nitric
xide synthase; LiESP, L. infantum excreted-secreted proteins; LTT, Lym-
hoblastic Transformation Test; NO, nitric oxide; PSA, parasite surface
ntigen; SLA, Soluble Leishmania Antigens.
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1. Introduction
Canine leishmaniasis (CanL), a complex disease caused
by an inappropriate immune response to infection with
Leishmania spp. (Leishmania infantum in the Mediterranean
basin) is a signiﬁcant problem for the canine population
and their owners in the world’s endemic areas (Solano-
Gallego et al., 2009). It is currently estimated that at least
2.5 million dogs are infected in southwestern Europe alone
(Moreno and Alvar, 2002), with the endemic area spread-
ing steadily northwards (Maroli et al., 2008). This provides
a large reservoir of infection with the potential for zoonotic
spread (Gramiccia and Gradoni, 2005).
ll rights reserved.
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The outcome of infection with L. infantum is highly vari-
able in dogs, with some progressing rapidly to the clinical
syndrome while others remain healthy (Solano-Gallego
et al., 2001). Data from the visceral form of the disease
in humans and from murine models of visceral leishman-
iasis have shown that a mixed response with a dominant
Th1 proﬁle is required for protection (McMahon-Pratt and
Alexander, 2004; Bhowmick and Ali, 2009; Sharma and
Singh, 2009). This also seems to be the case in dogs where
the response is always a complex balance between the
Th1 and Th2 proﬁles (Strauss-Ayali et al., 2007), and it is
now generally accepted that resistance to developing CanL
is primarily dependent on whether or not a dog devel-
ops an appropriate Th1-dominated cell-mediated immune
response against the parasite (Santos-Gomes et al., 2002;
Carrillo and Moreno, 2009). The protective response is
believed to be primarily mediated by the induction of
inducible nitric oxide synthase (iNOS) in macrophages
upon stimulation by Th1 cytokines such as IFN-. This
results in a leishmanicidal oxidative burst with a simulta-
neous increased production of leishmanicidal nitric oxide
(NO) and reduced production of the polyamides which are
essential for the growth and survival of the parasite within
the macrophage (Barbiéri, 2006; Zafra et al., 2008). It is
also probable that further to its direct leishmanicidal effect,
NO may  play additional immunoregulatory roles (Bogdan
et al., 2000). Despite the complexity of the situation, it is
now widely recognised that the ideal protective immune
response in the dog is mediated by a dominant CD4+ Th1
inﬂuence in an overall mixed cellular response (Santos-
Gomes et al., 2002; Carrillo and Moreno, 2009).
Therefore, there is a clear need to be able to reinforce a
dog’s immune response in order to increase the probabil-
ity that it will correctly manage the infection and remain
healthy. In addition, when the immune system correctly
controls parasite replication, this in turn reduces the num-
ber of dogs infectious to sandﬂies. It is for this reason that
several authors have expressed the opinion that an effec-
tive vaccine against CanL would be the best control strategy
for both canine and human disease in areas of the world
where transmission to humans is primarily zoonotic (Dye,
1996; Alvar et al., 2004).
This has been made possible for the ﬁrst time in Europe
by the relatively recent launch of the LiESP/QA-21 vaccine
(CaniLeish®, Virbac, France). This vaccine is licensed for
use with a primary vaccination course of three injections
at three week intervals, followed by annual booster vac-
cinations. It is very important to be able to understand as
much as possible about the mode of action of this vaccine on
the immune response of the dog. Data demonstrating the
onset of an appropriate Th1-dominated cellular immune
response after vaccination with the LiESP/QA-21 vaccine
has been published (Moreno et al., 2012). However, as with
any vaccine, the key objective is the ability to produce
an appropriate and speciﬁc memory response to infection
months or even years later. Thus, it is essential to demon-
strate that this response persists for a suitable period of
time in order to determine an appropriate revaccination
interval for the vaccine. Two other canine leishmanio-
sis vaccines (Leishmune®, Zoetis, and LeishTec®, Hertape
Calier) are available, but only in Brazil (Otranto andmunopathology 158 (2014) 199–207
Dantas-Torres, 2013). Both of these also have a primary
vaccination course consisting of three injections at three
week intervals followed by annual booster vaccinations.
This study aimed to assess the ability of the LiESP/QA-21
vaccine to stimulate an appropriate, speciﬁc, Th1-
dominated immune response against L. infantum in dogs for
at least 1 year after the last administration of the vaccine.
2. Materials and methods
2.1. Ethics statement
The study was  approved by the Ethical Committee of
Harlan Laboratories Bioservice GmbH, Germany.
2.2. Summary of the study design
This study compared the general characteristics of the
speciﬁc humoral and cellular immune responses against L.
infantum between unvaccinated and vaccinated dogs dur-
ing 1 year after a primary vaccination course.
2.3. Animals’ characteristics
20 conventional Beagle dogs (10 males and 10 females)
aged approximately 6 months old (between 5 months and 3
weeks, and 7 months old) on the day of the ﬁrst vaccination
were assigned to two  groups (10 vaccinated and 10 control)
according to their sex and litter of birth. There were 5 males
and 5 females per group.
All animals had previously been vaccinated with
conventional vaccinations against Distemper virus, Ade-
novirus, Parvovirus, Parainﬂuenza virus, Leptospira spp.
and Rabies before the beginning of the study, and annual
booster vaccinations for these valencies were given during
the study.
They were housed in controlled indoor kennel condi-
tions in a non-endemic country to avoid any possibility
of exposure to L. infantum parasites, and dewormed
with a combination product containing Febantel, Pyrantel
embonate and Praziquantel (Drontal® Plus ﬂavour, Bayer,
Germany) 1 week prior to the date of the ﬁrst administra-
tion of the LiESP/QA-21 vaccine and then again 7 months
later.
2.4. Vaccine and vaccination protocol
The LiESP/QA-21 vaccine is authorised in the Euro-
pean Union under the trade name CaniLeish® (Virbac,
France). It is composed of puriﬁed excreted-secreted pro-
teins of L. infantum (LiESP), produced by means of a
patented cell-free, serum-free culture system invented by
the Institut de Recherche pour le Développement (Patent
Application number FR 2 705 358, 1993, J Lemesre), and
adjuvanted with QA-21, a highly puriﬁed fraction of the
Quilaja saponaria saponin. The doses used in this study
were formulated at 100 gESP and 60 g QA-21. This is
consistent with the minimum accepted antigen levels in
commercially available doses. Each dose was reconstituted
immediately before use in 1 ml  0.9% NaCl solution.
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Dogs in the vaccinated group (n = 10) were given one
ose of the LiESP/QA-21 vaccine subcutaneously every 21
ays for a total of three doses. Vaccinations were adminis-
ered in the interscapular area. Dogs in the control group
n = 10) did not receive any vaccination. No additional
ooster vaccinations of LiESP/QA-21 were given to vacci-
ated dogs during the study.
.5. Clinical follow-up
The general health of each animal was observed daily,
nd speciﬁc attention was also given to the injection site
reas in the weeks following vaccination. The injection site
rea was clipped in both groups of dogs at the start of the
tudy to allow for easier, unbiased visual assessment and
alpation of any local reactions. In the absence of any sus-
ected problems which would trigger an additional full
linical examination, the animals received a routine full
linical examination including assessment of bodyweight
nd rectal temperature every one to two weeks during the
rst three months of the study, and then monthly there-
fter.
.6. Analyses and schedule
.6.1. Serology testing of the humoral immune response
ELISA testing was performed on the day of each vac-
ination (weeks 0, 3, 6) and also two weeks after the last
accination (week 8) and then on weeks 12, 30, 42, 54 and
nally on week 58 (1 year after the last vaccine adminis-
ration) to dose the level of IgG1 and IgG2 antibodies to
oth LiESP and also speciﬁcally to Parasite Surface Antigen
PSA), which is a major antigenic component of LiESP. Blood
as collected in uncoated tubes and the serum separated
efore performing the analyses.
On each occasion when ELISA testing was performed,
mmunoﬂuorescence testing (IFAT) was also performed on
he same samples to dose the level of total anti-Leishmania
gG antibodies.
Brieﬂy, the techniques were performed as follows:
.6.1.1. ELISA. A NUNC Maxisorp plate was coated with
ither 0.1 g ESP or 0.1 g PSA per well in carbonate buffer
0.16% sodium carbonate with 0.29% sodium bicarbonate,
H 9.6) for 90 min  at 35–37 ◦C. Non-speciﬁc sites were
locked with PBS-Tween (SIGMA, France) 0.5%-milk pow-
er (Régilait, France) 5% for 90 min  at 35–37 ◦C. Then serial
hree-fold dilutions of the serum to be tested, from 1/150 to
/12,150, were made in PBS-milk powder 0.5% buffer and
dded to the plate. After 60 min  of incubation at 35–37 ◦C
ny antibodies ﬁxed to the ESP or PSA, respectively, were
evealed with a speciﬁc peroxydase-conjugated polyclonal
nti-IgG1 or anti-IgG2 secondary antibody (Bethyl Labora-
ories, Montgomery, USA) and ABTS colouration. The titre
orresponded to the ﬁrst dilution with an optical density
t 405 nm inferior to 0.4. Dogs were considered as negative
hen the titre was inferior to 1/450..6.1.2. IFAT. The Fluoleish® kit (BVT, France) was  used
ccording to the manufacturer’s instructions using serial
ilutions of the serum from the 1/100th to 1/12,500th. Themunopathology 158 (2014) 199–207 201
titre in this test corresponded to the last dilution where at
least 50% of the parasites displayed visible ﬂuorescence.
For the graphical representation of the mean reciprocal
titres (in log10) of all serological analyses, dogs with nega-
tive results were regarded as having a result of zero after log
conversion of the reciprocal titres to allow these negative
results to be represented on the charts.
2.6.2. Cellular immune response assays
The three cell-mediated immunity tests, [Lymphoblas-
tic Transformation Test (LTT), IFN- Enzyme-Linked
Immunospot Assay (ELISpot) and Canine Macrophage
Leishmanicidal Assay (CMLA)] were performed as previ-
ously described, and as summarised below, at baseline
(week 0), three weeks after the third vaccination (week 9)
and thereafter on weeks 30 and 58 (1 year after the last
vaccine dose).
2.6.2.1. LTT. This assay was  used to reveal the ability of the
speciﬁc memory T cells produced as a result of vaccination
to proliferate after being exposed to Soluble Leishmania
Antigens (SLA). It was performed in a manner similar to that
previously described (Moreno et al., 1999; Carrillo et al.,
2008; Moreno et al., 2012).
Brieﬂy, heparinized blood samples were fractionated
by centrifugation over lymphocyte separation medium.
PBMCs obtained were incubated at a density of 106 cells/ml
for 5 days (37 ◦C, 5% CO2) in presence of either 10 g/ml
ConA, or 10 g/ml SLA, or with medium alone. The cells
were pulsed during the last 24 h with 10 M 5-bromo-2-
deoxyuridine (BrdU), which is incorporated into the DNA
of proliferating cells. BrdU incorporation was determined
with a speciﬁc ELISA system (GE Healthcare, Chalfont St.
Giles, UK) that uses peroxydase-labelled anti-BrdU anti-
bodies which are in turn detected by a substrate reaction
using 3,3′5,5′-tetramethylbenzidine. Absorbance values at
450 nm correlate directly to the amount of DNA synthe-
sis and thereby to the number of proliferating cells in
culture. The results were expressed as the lymphoprolifer-
ation index, which is the ratio of the mean optical density
obtained for the SLA stimulated samples compared to the
mean optical density obtained for the non-stimulated sam-
ples. ConA was  used as a positive control and the medium
alone was  used as a negative control.
2.6.2.2. ELISpot. This assay was  used to determine the
proportion of T cells that release IFN- after stimulation
with SLA in order to quantify the level of stimulation
of a speciﬁc Th1-polarity immune memory response. It
was performed in a manner similar to that previously
described (Holzmuller et al., 2005; Moreno et al., 2012).
Heparinized blood samples were fractionated by centrifu-
gation over lymphocyte separation medium. The PBMCs
obtained were incubated at a density of 106 cells/ml for
3 days in multiscreen HTS ﬁlter plates (Millipore, Biller-
ica, USA) previously coated with canine IFN- capture
antibody (R&D System, Minneapolis, USA), in presence of
10 g/ml ConA, or 10 g/ml SLA antigens, or with medium
alone, in a humidiﬁed 37 ◦C CO2 incubator. The quantity of
IFN- was  revealed with a speciﬁc biotinylated antibody
and incubation with Streptavidin-AP and the BCIP/NBT
y and Im202 J. Moreno et al. / Veterinary Immunolog
Chromogen (R&D System, Minneapolis, USA). The number
of speciﬁc spots was determined by an automated ELISpot
reader. ConA was used as a positive control and the medium
alone was used as a negative control. The data presented are
the number of spots per 2 × 105 cells after stimulation with
SLA minus the equivalent value obtained with the negative
control using medium alone.
2.6.2.3. CMLA. This assay was used to determine the
ability of monocyte-derived canine macrophages to kill
Leishmania parasites in a co-culture system due to the
stimulation of iNOS expression and the resulting produc-
tion of NO derivatives when the macrophage is exposed to
autologous lymphocytes derived from canine PBMC. It was
performed in a manner similar to that previously described
(Neogy et al., 1994; Vouldoukis et al., 1996, 2006; Moreno
et al., 2012).
Brieﬂy, monocytes separated from lymphocytes by
adherence were cultured at a density of 2 × 105 cells per
well at 37 ◦C and 5% CO2 for 6 days in complete RPMI 1640
medium containing 25 mM Hepes.
After 6 days of culture, monocyte-derived macrophages
were infected with stationary growth phase L. infantum
(MCAN/82/GR/LEM 497) promastigotes at a ratio of 1:5 for
5 h; then the cells were washed and fresh medium was
added for 24 h. This point was then considered as time
zero. The cells were checked to ensure that greater than
55% were infected. The infected cells (t0) were washed
and then 2 × 105 macrophages were incubated in each
well alone or in the presence of 105 autologous lympho-
cytes for 72 h in complete medium containing additionally
10 mM HEPES and 5 × 10−5 M 2-mercaptoethanol. After
72 h of co-culture, the lymphocytes were then removed by
several gentle washings, the cell free supernatants were
conserved for analysis and the macrophages were ﬁxed
in order to evaluate the leishmanial killing. One part of
the ﬁxed macrophages was stained with Giemsa and the
leishmanicidal activity was determined microscopically by
counting in triplicate the number of intact parasites per 100
cells in the macrophages co-cultured with the lymphocytes
and contrasting this with the number of intact parasites per
100 cells in the macrophages cultured with the medium
alone (no T cells). The difference between these results
was expressed as the CMLA index using the following for-
mula: CMLA index = 100 − (mean number of amastigotes
per macrophage multiplied by the percentage of infected
cells when co-cultured with lymphocytes)/(mean num-
ber of amastigotes per macrophage multiplied by the
percentage of infected cells when cultured without lym-
phocytes) × 100.
The other part of the ﬁxed macrophages was  used to
evaluate the % of inducible nitric oxide synthase (iNOS)
expression by immunolabelling with NOS speciﬁc anti-
bodies, as described previously (Vouldoukis et al., 2006).
Brieﬂy, the cells were incubated with rabbit polyclonal
antibodies directed against NOS (Santa Cruz Biotechnol-
ogy, USA) at a dilution of 1:100 in PBS for 1 h at 4 ◦C,
followed by 3 washes in PBS, then the binding of the anti-
body was revealed by use of a labelled anti-rabbit IgG in an
immunoﬂuorescence assay to determine the percentage of
iNOS positive macrophages.munopathology 158 (2014) 199–207
The production of NO2 (involved in the NO cascade) was
determined in the culture supernatants using the modi-
ﬁed Griess reference technique (Green et al., 1982). When
evaluating this leishmanicidal activity test, a result was
considered as successful, when the % inhibition of the par-
asitic index (CMLA) was associated with the activation of
the NO pathway and directly correlated with a signiﬁ-
cant increase of iNOS expression and the production of NO
derivatives.
3. Statistical analyses
All statistical tests were performed using the SAS v9.1
software, and for all analyses the signiﬁcance threshold was
set at p = 0.05.
Assessments for bodyweight, rectal temperature, LTT,
ELISpot, CMLA, NO2 and iNOS were performed by use of lin-
ear mixed-effects models including group, time and their
interaction as ﬁxed effects the dog as a random effect.
Where signiﬁcant differences were found in the lin-
ear mixed-effects models, Wilcoxon two-sample tests were
also used to assess the differences between groups at each
time point.
4. Results
4.1. Growth and rectal temperatures
During the study period both groups of dogs grew
normally with no signiﬁcant differences between them.
Some dogs in each group (5 vaccinated and 5 control
dogs) presented single-day rectal temperatures slightly
above the normal range. This was  not associated with any
clinical signs and was  unrelated to the administration of
the vaccine in the vaccinated group. These episodes were
attributed to excitement and handling of the animals.
4.2. Clinical condition
Minor clinical signs were observed in both groups before
the commencement of the vaccination course including
conjunctivitis and mild swelling of the cervical lymph
nodes. During the one-year course of the study, some minor
clinical signs such as conjunctivitis, skin irritation at sites
clipped for blood sampling and minor wounds were noted
in nine of the vaccinated dogs and all the unvaccinated con-
trol dogs. None of these were related to vaccination. No
adverse events (local or systemic) were reported after any
vaccination.
4.3. Serology testing of the humoral immune response
At the start of the study, all animals were negative for
antibodies against L. infantum by all the tests used. No con-
trol dogs were positive by any serological test at any point
during the study.
After vaccination, all LiESP/QA-21 vaccinated dogs
developed a strong IgG2 response to both ESP (range
1/1350–1/12,150) and, in particular, to PSA (range
1/450–1/4050). Six months after the vaccine course (week
30) all vaccinated dogs still had detectable IgG2 titres to
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Fig. 1. Progression in log-transformed anti-ESP IgG1 and IgG2 titres dur-
ing  primary vaccination and the subsequent year. The data presented here
are the means of the log-transformed reciprocal titres in the vaccinated
group (n = 10). The titre is taken to be the ﬁrst dilution with an optical
density of less than 0.4 measured at 405 nm.  The sera were tested using
an ESP-coated ELISA. The ESP used was identical in proﬁle to the anti-
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Fig. 3. Progression in log-transformed anti-L. infantum IgG titres during
one year after primary vaccination. The data presented here are the means
of  the log-transformed reciprocal titres in both vaccinated (n = 10) and
control (n = 10) dogs. The titre is taken to be the last dilution where at
least 50% of the parasites display visible ﬂuorescence. The sera were tested
No signiﬁcant leishmanicidal activity was  detected for
any dog at week 0, and there was  no statistical differenceen of the vaccine. Dogs with a negative result were regarded as having a
esult of zero after log conversion of the reciprocal titres to allow this to
e  represented on the charts.
SP. At the end of the study, 5 vaccinated dogs still had
etectable IgG2 titres against ESP, and 1 had a detectable
itre against PSA (see also Figs. 1 and 2).
All vaccinated dogs also developed an IgG1 response to
SP by week 8 (range 1/450–1/4050). By week 30, only 4
accinated dogs still had detectable IgG1 titres against ESP.
Only one vaccinated dog developed a detectable IgG1
nti-PSA response (maximum titre 1/1350), which was evi-
ent only from week 8 to week 12 (see also Figs. 1 and 2).
All vaccinated dogs were also positive by IFAT on week
 and week 12 (maximum titre 1/500) and one vaccinated
og still had a titre of 1/200 on week 30. All dogs were
egative by IFAT (<1/200) on week 42 (see Fig. 3).
.4. Cellular immune response assays
.4.1. LTT
The PBMCs of all animals in both vaccinated and control
roups were able to respond effectively to the non-speciﬁc
ositive control stimulation with ConA (no difference
etween groups, data not shown, p = 0.235). A compari-
on of the result after SLA stimulation at each time point is
hown in Fig. 4. There was a signiﬁcant difference between
ig. 2. Progression in log-transformed anti-PSA IgG1 and IgG2 titres dur-
ng primary vaccination and the subsequent year. The data presented here
re the means of the log-transformed reciprocal titres in the vaccinated
roup (n = 10). The titre is taken to be the ﬁrst dilution with an optical
ensity of less than 0.4 measured at 405 nm.  The sera were tested using
 PSA-coated ELISA. PSA is a dominant antigen in ESP and therefore a key
ntigen in the vaccine. Dogs with a negative result were regarded as hav-
ng  a result of zero after log conversion of the reciprocal titres to allow
his to be represented on the charts.using commercially available IFAT kit. Dogs with a negative result were
regarded as having a result of zero after log conversion of the reciprocal
titres to allow this to be represented on the charts.
the groups over the course of the study in a linear mixed
effect model (p = 0.0025). The p-values of the comparison
between groups at each time point are displayed in Fig. 4
where these are <0.05.
4.4.2. ELISpot
The PBMCs of all animals in both vaccinated and control
groups were able to respond effectively to the non-speciﬁc
positive control stimulation with ConA (no difference
between groups, data not shown, p = 0.235). A compari-
son of the result after SLA stimulation at each time point is
shown in Fig. 5. There was  a signiﬁcant difference over time
as assessed by a linear mixed effects model (p = 0.0214). The
p-values of the comparison between groups at each time
point are displayed in Fig. 5 where these are <0.05.
4.4.3. CMLAbetween groups for any of the three parameters tested in
this assay at week 0.
Fig. 4. Lymphoproliferation index before and for 1 year after the comple-
tion of the primary vaccination course. This assay detects the ability of
the  speciﬁc T cells produced as a result of vaccination to proliferate after
being exposed to Soluble Leishmania Antigens (SLA). The lymphoprolifer-
ation index is the ratio of the mean optical density obtained for the SLA
stimulated samples compared to the mean optical density obtained for the
non-stimulated samples using a BrdU speciﬁc ELISA system. There were
10  dogs per group. There was  a signiﬁcant difference between the groups
over the course of the study in a linear mixed effect model (p = 0.0025).
The p-values for the difference between groups at speciﬁc time points as
assessed using a Wilcoxon two-sample test are noted where these are
<0.05.
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Fig. 5. ELISpot detection of IFN- secreting lymphocytes before and for
1  year after the completion of the primary vaccination course. This assay
detects the ability of lymphocytes to secrete IFN- after speciﬁc stimu-
lation with Soluble Leishmania Antigens (SLA) by detecting spots (which
represent a clone of cells secreting IFN-) using speciﬁc biotinylated anti-
bodies and an automated ELISpot reader. The data presented here are the
number of spots per 2 × 105 cells after stimulation with SLA minus the
equivalent value obtained with the negative control using medium alone.
There were 10 dogs per group. There was a signiﬁcant difference over time
Fig. 6. CMLA assay: inhibition of the macrophage parasitic index, iNOS
activity and production of NO derivatives.
Error bars denote the standard error of the means. Data are presented
for  week 0 (immediately before starting the primary vaccination course),
week 9 (three weeks after the completion of the primary vaccination
course), and then weeks 30 and 58 (which is one year after completion of
the primary vaccination course). There were 10 dogs per group.
Panel A is a comparison of the ability of the dogs’ macrophages to inhibit
parasite multiplication after interaction with autologous lymphocytes.
The CMLA index is obtained by comparing the number of intact parasites
in  artiﬁcially infected monocyte-derived macrophages when they are co-
cultured with autologous lymphocytes for three days (beginning one day
after the infection of the macrophages) in contrast to those with medium
alone. This panel demonstrates the increase in the leishmanicidal capacity
of the dogs’ macrophages as a result of vaccination.
Panel B is a comparison of the rate of expression of iNOS in the dogs’
macrophages after 3 days of exposure to autologous lymphocytes. The
expression of iNOS is measured by immunolabelling with NOS speciﬁc
antibodies.
Panel C is a comparison of the rate of production of NO derivatives from
the dogs’ macrophages during co-culture with autologous lymphocytes,
and is expressed in nmol NO2 per 105 cells per 72 h. NO2 is determined in
the  culture supernatants using the modiﬁed Griess technique, providing
a  correlation with the production of the short-lived NO radical.
When these three measurements are consistent, this provides evidence of
an increased NO-mediated pathway of parasite killing as a result of vacci-
nation. There was  a highly signiﬁcant difference between the groups over
time (p < 0.0001) for all three parameters. Between week 9 and the end ofas  assessed by a linear mixed effects model (p = 0.0214). The p-values for
the difference between groups at speciﬁc time points as assessed using a
Wilcoxon two-sample test are noted where these are <0.05.
In the control group the results for all three parameters
rose slightly by week 9, but no dog reached the threshold
in any parameter throughout the study.
In the vaccinated group, a signiﬁcant rise was seen in
all three parameters by week 9, and all dogs remained
above the threshold for all three parameters for the remain-
der of the study. There was a highly signiﬁcant difference
between the groups over time (p < 0.0001) for all three
parameters. Between week 9 and the end of the study
the results for the vaccinated dogs remained signiﬁcantly
higher than those for the control dogs in all three param-
eters at every time point (see Fig. 6a–c, where * signiﬁes
p = 0.0002).
5. Discussion
The results of this study were broadly in line with those
of a previous study published by our group, in which we
assessed the same parameters during the initial vaccination
phase up until 3 weeks after the third vaccination (Moreno
et al., 2012).
Once again it has been conﬁrmed that the antibody
proﬁle induced by the vaccine is predominantly IgG2. How-
ever, the current study demonstrates that the IgG2 titres
are not only higher but also more persistent than the
IgG1 titres. Although a correlation between antibodies of
the IgG1 subtype and a Th2 response, and antibodies of
the IgG2 subtype and a Th1 response has been demon-
strated in mice (Heinzel et al., 1989) the IgG1/IgG2 ratio
has not been correlated with protection or resistance in
dogs (Day, 2007a). Nevertheless, a previous study using
a prototype LiESP vaccine formulated with MDP adjuvant
found that the IgG2 induced by vaccination was function-
ally active in that it was leishmanicidal to both amastigotes
and promastigotes, and could also reduce the infectivity
of pre-treated amastigotes to canine macrophages in vitro
(Bourdoiseau et al., 2009). Even if the main determinant
of resistance to canine leishmaniasis is an effective Th1-
dominated cell-mediated response, IgG2, which is effective
in opsonisation and complement ﬁxation, may  still bethe study the results for the vaccinated dogs remained signiﬁcantly higher
than those for the control dogs in all three parameters at every time point
(*  signiﬁes p = 0.0002).
able to play a complementary role by targeting individ-
ual amastigotes released from infected macrophages (Day,
2007a).
The fact that the IFAT results were positive, and in
some cases at more than 4 times the laboratory thresh-
old for a short time after vaccination, conﬁrms that caution
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s required in the interpretation of such results in dogs
accinated under ﬁeld conditions. Until the advent of vac-
ination in Europe, standard guidelines suggested that
FAT titres of at least 4 times the laboratory cut-off level
ere indicative of the disease, and that levels between the
hreshold and 4 times the threshold raised a suspicion of
he disease (Solano-Gallego et al., 2009). IFAT is a non-
peciﬁc test that detects IgG antibody ﬁxation to whole
arasites. As some of the component proteins of the LiESP
re found in both surface and excreted forms, it was not
nexpected to obtain such a result.
In light of the clear consensus that a Th1-dominated
roﬁle within a mixed Th1/Th2 response is the most desir-
ble outcome for protection in the dog (Baneth et al., 2008),
he most important data in this paper are those relating to
ellular immunity. In this study, we chose to assess some
ey markers of the appropriate Th1 response. The choice
f markers studied was based on the knowledge available
t the time, and also on the availability of validated assays
s required in a study conducted with a view to vaccine
egistration. Consequently, not all possible markers could
e assessed. For example, it would have been interesting to
ook at the IL-10/IFN- ratio as IL-10 is a key marker of the
h2 proﬁle, and some studies have suggested that in the
resence of very high levels of IL-10, even signiﬁcant IFN-
 production may  not be effective (Alexander and Bryson,
005). The lack of a validated assay at the time of the study
recluded this analysis. Likewise, it appears that IFN- from
timulated PBMCs is insufﬁcient alone, and other co-factors
uch as TNF- are also required for an effective response in
ogs, mice and human beings (Nacy et al., 1991; Vouldoukis
t al., 1995; Carrillo and Moreno, 2009). However, the fact
hat we also included the CMLA assays in this study ade-
uately compensates for any apparent lack. In the CMLA
ssay, the functional interaction between the T lympho-
ytes and the macrophages is assessed. Therefore, if there
ere a dominant inhibitory IL-10 effect blocking the abil-
ty of IFN- to stimulate the macrophages’ leishmanicidal
ctivity, or an inability to produce the TNF- cofactor, this
ffect would have been seen in the CMLA results. Indeed
t has been previously demonstrated that IL-10 inhibi-
ion of Leishmania killing correlates with a decrease in NO
eneration and down-regulated leishmanicidal activity in
acrophages (Vouldoukis et al., 1997). The positive results
btained in our CMLA assay therefore clearly conﬁrm that
he dominant effect of macrophage activators such as IFN-
s not abolished by a lack of TNF- or an excess of IL-10, and
onﬁrm that the overall response is indeed Th1-dominated.
In the CMLA assays it is not simply the ﬁnal reduction
f the macrophage parasite load that is demonstrated, but
lso a correlation between this and the currently under-
tood mode of action of an effective immune response
 a leishmanicidal oxidative burst due to Th1 cytokine-
ediated induction of iNOS leading to production of NO
Vouldoukis et al., 1996; Noël et al., 2004; Holzmuller
t al., 2005; Perez et al., 2006; Wanasen and Soong, 2008).
his greatly reinforces conﬁdence in the results relating
o the leishmanicidal effects. While it would also have
een interesting to assess the presence of alternatively
ctivated macrophages, permissive to the parasite devel-
pment (Vouldoukis et al., 1997), it was not possible in thismunopathology 158 (2014) 199–207 205
study, and in any case the CMLA results reﬂect the global
picture created by the ensemble of all the macrophage
types present.
In a recent review (Reis et al., 2010) the authors
concluded that, amongst others, Leishmania-speciﬁc IgG
isotype levels, IFN- expression, the proliferative response
to leishmanial antigen and the leishmanicidal activity
in macrophages were valuable, reliable and measurable
biomarkers when determining the immunogenicity of vac-
cines against canine leishmaniasis. However, despite also
considering IL-10 in their review, there did not appear to be
sufﬁcient evidence in dogs for them to propose this marker
for canine studies in their conclusions. The choice of param-
eters in this study therefore remains in line with the current
literature.
As noted in our previous study, which assessed the onset
of immunity (Moreno et al., 2012), there was a slight but
non-signiﬁcant rise in the CMLA responses in the control
group in this study. In the previous work, we  hypothesised
that this may  simply be due to the age of the dogs and the
natural maturation of the cell-mediated arm of the adap-
tive immune response, which is slower than that of the
humoral response (Day, 2007b). The fact that in the current
study the initial rise, which was noted during the period of
maturation of the dogs, levelled off subsequently and did
not change further lends additional support to this hypoth-
esis. Regardless of this slight rise in the control group, the
differences between groups were marked and highly sig-
niﬁcant throughout the full period of the study after the
onset of immunity in the vaccinated group.
It is accepted that no single marker is sufﬁcient to
be a direct correlate of protection or susceptibility to
canine leishmaniasis as the effective immune response
operates as a complex network of regulatory and counter-
regulatory interactions involving multiple cytokines and
cell types (Day, 2007a; Resende et al., 2013). However, it
is possible to consider multiple parameters together and
to obtain a general view of the overall direction of the
immune response. The concept of a dynamic spectrum
in the immune responses of dogs, where the overall bal-
ance of the various factors present in the mixed Th1/Th2
response will determine the ﬁnal outcome was  recently
proposed (Reis et al., 2010). Accepting this model, the
current study clearly demonstrated the ability of vaccina-
tion with LiESP/QA-21 to induce an appropriate immune
response and to maintain this for a full year. While no
speciﬁc assessment was made using cell-surface markers
for the presence of Leishmania-speciﬁc memory T cells, it
is clear that an effective response obtained one year after
vaccination in animals that had never been exposed to the
infectious agent will be due to the presence of such cells.
Despite the obvious limitations of an in vitro analysis
of immune proﬁle parameters in the face of the complex-
ity of the immune response induced in vivo, the results
obtained in this study strongly support the expectation
of an effective response in vivo, and the ability of vacci-
nated dogs to control their parasite burdens when exposed
to virulent parasites. It would be necessary to conﬁrm the
effectiveness of this immune proﬁle using a virulent chal-
lenge to allow any conclusion to be drawn regarding its
correlation with clinical protection. In addition, it must be
y and Im206 J. Moreno et al. / Veterinary Immunolog
recognised that this study was performed in a relatively
small, homogenous group of beagles, and so it is possible
that in a wider and more varied population the range of
responses could be slightly different. Nevertheless, for a
study such as this it is important to have groups which
are as similar and standardised as possible to eliminate
the interference of variables other than the effects of the
vaccine on the canine immune response.
6. Conclusion
The results presented here conﬁrm that vaccination
with LiESP/QA-21 is capable of stimulating an appropri-
ate Th1-dominated cell-mediated immune response that is
still present 1 year after the last injection of a primary vac-
cine course. This supports an expectation of in vivo efﬁcacy
that must be assessed by virulent challenge in vaccinated
dogs.
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